PA-TELEFLEX
11.3.2021 08:02:06 CET | Business Wire | Press release
Teleflex Incorporated (NYSE: TFX)– Men in France living with Benign Prostatic Hyperplasia (BPH), a condition in which the prostate enlarges as men get older and can cause significant discomfort, will now be offered a newly available minimally invasive treatment on the public health care system, the UroLift® System. The proven procedure, developed by medical technology provider Teleflex to treat lower urinary tract symptoms due to BPH, is now reimbursable under French mandatory health insurance for the first time.
Following a positive Haute Autorité de Santé (HAS) assessment, a procedure code has been granted allowing hospitals to offer the UroLift System to men over 50 years of age who show symptoms of an enlarged prostate up to 100cc. † Approximately 250,000 people have already been treated with the device worldwide* and it is estimated that, in France, between 3,400 and 6,900 patients could benefit from the procedure each year.1
Unlike more invasive surgical treatments and prescription medicines which can lead to erectile or ejaculatory dysfunction, the UroLift System is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction, while being safe and effective.2,3,4, It has demonstrated a more positive impact on quality of life than reported for patients on pharmaceutical medications. 2,3
In those living with BPH, the prostate can press on and block the urethra, potentially causing an urgent need to urinate, and a need to urinate frequently, among other symptoms. It is estimated that almost two million men live with the condition in France.5 The UroLift permanent implants, delivered during an outpatient procedure, can relieve prostate obstruction without cutting, heating, or removing prostate tissue. Patients typically can return home the same day without a catheter and experience rapid symptom relief and recovery with low complication rates.6,7
Matt Wiggins, Interventional Urology General Manager, EMEA, said: “Today’s decision means men in France finally have a safe and effective treatment option which does not compromise on sexual function.**2 As patients can be treated with the UroLift System in an ambulatory setting, rather than a classical operating theatre, and allows patients to be discharged quickly, usually without a catheter, it gives French urologists a new way to relieve some of the pressure on resources caused by the COVID-19 pandemic and pause on elective surgeries.6,7 The UroLift System has the potential to save hours of theatre time and bed days, while reducing complications and waiting lists, making it a timely alternative for those wishing to ease the strain on current services.8,9 ”
About the UroLift® System
The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 50 years or older. As with any medical procedure, individual results may vary. The UroLift permanent implants, delivered during an outpatient procedure, relieve prostate obstruction without cutting, heating, or removing prostate tissue. The UroLift System is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction in the L.I.F.T pivotal study.1 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.1 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information. The Prostatic Urethral Lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. Approximately 200,000 men have been treated with the UroLift System in select markets worldwide.* As with any medical procedure, individual results may vary. Learn more at www.UroLift.com .
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com .
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com .
Teleflex is the home of Arrow® , Deknatel® , Hudson RCI® , LMA® , Pilling® , Rusch® , UroLift® System and Weck® – trusted brands united by a common sense of purpose.
MAC01749-02 Rev A:
* Management estimate based on product sales and average units per procedure
** No instances of new onset, sustained erectile or ejaculatory dysfunction in the L.I.F.T pivotal study
† Contraindications: The UroLift System should not be used if the patient has; a prostate volume >100cc, a urinary tract infection
1. https://www.has-sante.fr/upload/docs/evamed/CNEDIMTS-6011_UROLIFT_05_novembre_2019_(6011)_avis.pdf
2. Roehrborn et al. Can J Urol 2017
3. AUA Guidelines 2003
4. McVary, J Sex Med 2014
5. NeoTract OUS Market Model estimates for 2021
6. Shore, Can J Urol 2014
7. Roehrborn, J Urology 2013
8. Orlowski ISPOR 2018
9. NICE Shared Learning Case Study – UroLift Norfolk and Norwich NHS Trust. 2016
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005798/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom